Today: 30 April 2026
Browse Category

ASX:TLX 11 December 2025 - 10 April 2026

Telix (ASX:TLX) share price jumps 14% on 2026 revenue outlook — what moved the stock

Telix (ASX:TLX) share price jumps 14% on 2026 revenue outlook — what moved the stock

Telix Pharmaceuticals shares closed up 14.2% at A$10.43 in Sydney after reporting 2025 revenue rose 56% to US$803.8 million and forecasting 2026 revenue of US$950 million to US$970 million. The company filed for European approval of its TLX101-Px brain cancer imaging agent earlier in the week. Telix ended 2025 with US$141.9 million in cash and posted a US$5.3 million pre-tax loss.
20 February 2026
··
Telix stock price slides 8% as investors digest FY25 revenue update and China Illuccix filing

Telix stock price slides 8% as investors digest FY25 revenue update and China Illuccix filing

Telix Pharmaceuticals shares fell 7.7% to A$10.61 at Wednesday’s close after the company reported unaudited FY2025 revenue in line with guidance and noted early momentum for Gozellix. China’s drug regulator accepted the Illuccix application, triggering a formal review. Investors weighed ongoing U.S. regulatory developments and recent clinical trial results.
21 January 2026
··
Telix Pharmaceuticals (TLX) Stock Slides on Dec. 17, 2025: ProstACT Phase 3 Update, FDA Zircaix Overhang, Lawsuit Headlines, and Fresh Analyst Forecasts

Telix Pharmaceuticals (TLX) Stock Slides on Dec. 17, 2025: ProstACT Phase 3 Update, FDA Zircaix Overhang, Lawsuit Headlines, and Fresh Analyst Forecasts

Telix Pharmaceuticals shares fell 6.61% to A$11.73 on the ASX December 17, with volume at 6.36 million and a 52-week low of A$11.535. Nasdaq-listed shares dropped 6–7% in early U.S. trading. The company issued a statement confirming completion of Part 1 enrollment in its ProstACT Global Phase 3 study after market rumors. TLX591 has not received marketing authorization.
17 December 2025
···
Telix Pharmaceuticals (TLX) Stock: Varian Deal, ProstACT Milestone and Class Actions Redraw the 2025 Outlook

Telix Pharmaceuticals (TLX) Stock: Varian Deal, ProstACT Milestone and Class Actions Redraw the 2025 Outlook

Telix Pharmaceuticals shares fell 6% to US$9.33 in New York on December 11, near a 52-week low, despite trailing 12-month revenue of US$664 million and a new clinical partnership with Varian. The company faces SEC scrutiny, an FDA setback, and multiple class-action lawsuits, but continues to report late-stage oncology progress and expanding collaborations.
11 December 2025
···

Stock Market Today

  • Adisyn Raises A$14 Million in Discounted Equity Offering, Altering Capital Structure Dynamics
    April 30, 2026, 11:30 AM EDT. Adisyn Ltd (ASX:AI1) secured A$14 million via a discounted equity raise, issuing 204.4 million shares at A$0.0675 each, a A$0.00405 per share discount. This significant capital infusion expands its share base and provides cash to fund R&D in 2D Radar Absorbers and integration of acquisitions. The move underlines management's commitment to public market funding but heightens dilution risk for existing shareholders. Investors face a dichotomy: a stronger cash position supporting defence and AI projects alongside ongoing losses and execution risks. Valuation estimates vary widely, from A$0.0023 to A$0.56 per share, emphasizing divergent market views. Adisyn's funding strategies and governance remain key focus areas as the company seeks commercial traction amid a challenging investment landscape.

Latest article

Everspin Technologies Stock Surges After $40 Million Defense MRAM Deal Puts Growth Back in View

Everspin Technologies Stock Surges After $40 Million Defense MRAM Deal Puts Growth Back in View

30 April 2026
FatPipe shares jumped 18% to $2.92 Thursday after the company announced expanded access to its SD-WAN and cybersecurity products through public-sector procurement channels. The move follows a VeloCloud replacement program targeting customers of Arista Networks’ SD-WAN business. Trading volume reached 42.2 million shares. Investors remain cautious over execution and customer concentration risks.
Why Huachen AI Parking (HCAI) Stock Is Surging: Tiny Float, Reverse Split and Nasdaq Risk

Why Huachen AI Parking (HCAI) Stock Is Surging: Tiny Float, Reverse Split and Nasdaq Risk

30 April 2026
Huachen AI Parking shares surged as much as 135% in heavy Nasdaq trading Thursday, triggering four volatility halts. No new company filings or press releases explained the spike. The rally follows a 1-for-30 reverse stock split effective April 13, which sharply reduced the share count. Trading volume reached 34 million shares, far above the average of 727,390.
Altria Stock Jumps 7% After Marlboro Maker Beats Q1 Forecasts on Price Hikes

Altria Stock Jumps 7% After Marlboro Maker Beats Q1 Forecasts on Price Hikes

30 April 2026
Altria posted adjusted earnings of $1.32 per share and net revenues of $5.43 billion for the quarter, beating analyst estimates. Higher prices offset falling cigarette volumes, with domestic shipments down 2.4%. Shares rose about 7% in late-morning trading. CEO Billy Gifford is set to step down in mid-May.
Go toTop